Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05427383 | KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy | recruiting | Phase 2 / Phase 3 | 286 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 19, 2023 | clinicaltrials |
| NCT06109402 | Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 160 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 19, 2023 |
| NCT06173986 | Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer | recruiting | Phase 1 / Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT06172036 | Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab(CAPT-02) | not yet recruiting | Phase 2 | 180 | Zhejiang UniversityOTHER | 0 | Dec 15, 2023 | clinicaltrials |
| NCT06155383 | Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. | recruiting | Phase 2 | 90 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 14, 2023 | clinicaltrials |
| NCT06170710 | Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC | recruiting | Phase 2 | 173 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT04242017 | Long-term Better Than Short-term ADT With Salvage RT(LOBSTER) | recruiting | Phase 2 / Phase 3 | 394 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06159478 | Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)(Perfume) | recruiting | Phase 2 | 32 | National Cancer Center, JapanOTHER_GOV | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03289299 | Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant(ASCENT) | active not recruiting | Phase 2 | 87 | International Myeloma FoundationOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT06166589 | Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer | not yet recruiting | Phase 2 | 19 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT06121271 | Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications | not yet recruiting | Phase 2 | 110 | University College, LondonOTHER | 0 | Dec 7, 2023 | clinicaltrials |
| NCT04379739 | Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 89 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06158269 | DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma | recruiting | Phase 2 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT05788679 | A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS | recruiting | Phase 2 | 200 | Karolinska University HospitalOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04729543 | MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer(MC2TCR) | recruiting | Phase 1 / Phase 2 | 20 | Erasmus Medical CenterOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT04045717 | Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0 | active not recruiting | Phase 2 | 124 | Universitaire Ziekenhuizen KU LeuvenOTHER | 2 | Dec 1, 2023 | clinicaltrials |
| NCT05694312 | Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL | recruiting | Phase 2 | 45 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT06152978 | A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 182 | Fudan UniversityOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT04214366 | Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation(ACCO) | recruiting | Phase 2 | 314 | Heidelberg UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT05978648 | Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy(SMA-BC-002) | recruiting | Phase 2 | 116 | wang shusenOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT06128460 | Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer. | not yet recruiting | Phase 2 | 24 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 0 | Nov 30, 2023 | clinicaltrials |
| NCT05627115 | Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma(RATiFY) | not yet recruiting | Phase 2 | 80 | University College, LondonOTHER | 0 | Nov 29, 2023 | clinicaltrials |
| NCT05923008 | A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 182 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT06149767 | Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer | not yet recruiting | Phase 2 | 26 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 29, 2023 | clinicaltrials |
| NCT03459820 | Prostate Cancer Patient Management With 18F-DCFPyL PET/CT | enrolling by invitation | Phase 2 / Phase 3 | 1,500 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Nov 27, 2023 | clinicaltrials |
| NCT06147570 | A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | recruiting | Phase 2 | 62 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT04718883 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma | active not recruiting | Phase 2 | 59 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05451784 | Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS(TILS001) | recruiting | Phase 1 / Phase 2 | 20 | Fundacio Clinic BarcelonaOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT02290145 | Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage | recruiting | Phase 2 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05069857 | Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients | recruiting | Phase 2 | 46 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05125055 | Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC | recruiting | Phase 2 / Phase 3 | 80 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05810792 | Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer(PANCEP-1) | not yet recruiting | Phase 2 | 50 | Sahlgrenska University HospitalOTHER | 0 | Nov 22, 2023 | clinicaltrials |
| NCT05961124 | Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer | recruiting | Phase 2 | 40 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06144723 | Study of HS-20105 for Injection in Patients With Advanced Solid Tumors. | not yet recruiting | Phase 1 / Phase 2 | 402 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Nov 22, 2023 | clinicaltrials |
| NCT06142617 | A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation. | not yet recruiting | Phase 2 | 37 | Peking Union Medical College HospitalOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06140576 | The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial. | not yet recruiting | Phase 1 / Phase 2 | 58 | Zhejiang Cancer HospitalOTHER | 1 | Nov 20, 2023 | clinicaltrials |
| NCT06132217 | A Study of Simmitinib Plus SG001 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 168 | Shanghai Runshi Pharmaceutical Technology Co., LtdINDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT06132711 | Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma(CAR-T) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT06133556 | Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML | not yet recruiting | Phase 2 | 237 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Nov 15, 2023 | clinicaltrials |
| NCT06130332 | Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004) | recruiting | Phase 2 | 40 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT03319628 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | active not recruiting | Phase 1 / Phase 2 | 523 | Mersana TherapeuticsINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06129851 | Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer | not yet recruiting | Phase 2 | 90 | University of Kansas Medical CenterOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05344209 | Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer(LUNGVAC) | recruiting | Phase 2 | 138 | Vestre Viken Hospital TrustOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06125652 | Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06121700 | Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer(Miracle-G) | recruiting | Phase 2 | 55 | Fudan UniversityOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06122493 | Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 48 | Ruijin HospitalOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05494060 | XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma(EXPLORING) | recruiting | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06114225 | Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial(PROMIS) | recruiting | Phase 2 | 43 | Ruijin HospitalOTHER | 1 | Nov 2, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Dec 19, 2023source: clinicaltrials